Artículos del autor

solaci

Day 3

J- REVERSE: sirolimus-eluting vs. everolimus-eluting stent in bifurcation lesions

Asymmetrical expansion of the stent produces an uneven neointimal growth and increases the risk of thrombosis. The...
solaci -
Day 2

BuMA stent: new sirolimus-eluting stent with bio-degradable polymer

Uncovered struts compromise re-endothelization and may induce thrombosis. The new stent approved in China and already used...
solaci -
Day 2

EXPAND: expanding the applications of bioresorbable platforms

There is little information about the use of bioresorbable vascular devices in patients with a reference diameter...
solaci -
Day 2

PROTAVI-C: Embolic protection during TAVI

Percutaneous aortic valve replacement (TAVI) is a new treatment option for patients that are inoperable or present...
solaci -
Day 2

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device...
solaci -
Day 2

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve...
solaci -
Day 2

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being...
solaci -
Day 2

DIRECT: results of drug-eluting stent-on-a-wire after 6 months

This balloon expandable stent is combined with a guide 0.014 in its distal part. The platform is...
solaci -